Screener
Syndax Pharmaceuticals SNDX Total Assets
Total Assets at other companies
Other financials
Where this comes from
Reported directly by Syndax Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:Assets.
The source filing: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 4:04 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-197154
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Property and equipment, net | 177 | 181 |
| Right-of-use asset, net | 1,212 | 1,342 |
| Restricted cash | 102 | 102 |
| Total assets | $472,668 | $529,706 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $10,843 | $16,580 |
| Accrued expenses and other current liabilities | 74,843 | 103,064 |
Item 1: Financial Statements
FAQ
- What is Syndax Pharmaceuticals's total assets?
- Syndax Pharmaceuticals (SNDX) reported total assets of $472.67M in Q1 2026.
- How has Syndax Pharmaceuticals's total assets changed year-over-year?
- Syndax Pharmaceuticals's total assets decreased by 26.2% year-over-year, from $640.71M to $472.67M.
- What is the long-term trend for Syndax Pharmaceuticals's total assets?
- Over 5 years (2020 to 2025), Syndax Pharmaceuticals's total assets has grown at a 12.0% compound annual growth rate (CAGR), from $300.61M to $529.71M.
- What does total assets mean?
- The sum of everything the company owns — current assets, property, investments, goodwill, intangibles, and all other assets.
Ask your AI about Syndax Pharmaceuticals's total assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude